Lilly’s ACHIEVE-4 trial has yielded promising results for Foundayo (orforglipron), a novel oral glucagon-like peptide-1 receptor agonist. This Phase 3 study, the longest to date, demonstrated that Foundayo met its primary objective of non-inferiority compared to insulin glargine, showing a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events. Notably, a pre-planned analysis revealed a 57% reduction in all-cause mortality for patients treated with Foundayo versus those on insulin glargine, highlighting its potential for broader health benefits beyond glycemic control.

The significance of these findings lies in the consistent safety and efficacy profile of Foundayo across seven Phase 3 studies involving over 11,000 patients. The trial confirmed a 16% lower risk of cardiovascular death, heart attack, stroke, or hospitalization for unstable angina, meeting the prespecified criteria for non-inferiority. Additionally, Foundayo showed clinically meaningful improvements in cardiovascular risk factors, including reductions in non-HDL cholesterol, systolic blood pressure, triglycerides, and hsCRP. The overall safety profile remained consistent with previous studies, with common adverse events primarily involving gastrointestinal symptoms.

The implications of these results are substantial for the field of diabetes and cardiometabolic health. As Lilly prepares to submit Foundayo for regulatory approval in treating type 2 diabetes, this trial could shift current research paradigms by emphasizing the importance of cardiovascular outcomes in diabetes management. Furthermore, the strong safety profile and efficacy data may accelerate the development timelines for similar GLP-1 receptor agonists, potentially reshaping therapeutic strategies aimed at improving healthspan and reducing mortality in patients with type 2 diabetes and obesity.

Source: investor.lilly.com